Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0264518
Abstract: Celecoxib (CLB) is a highly hydrophobic selective cyclo-oxygenase inhibitor with high plasma protein binding and undergoes extensive hepatic metabolism. CLB is highly effective in the treatment of osteo and rheumatoid arthritis as first line therapy… read more here.
Keywords: celecoxib; side effects; stealth; stealth liposomes ... See more keywords